Navigation

2006/048 NICE announces Alzheimer's disease drug appeal outcome and NHS guideline to support patients and carers

NICE has today (Wednesday 11 October) announced that the appeals lodged by stakeholders against draft guidance on the use of drugs to treat Alzheimer's Disease have not been upheld. NICE will recommend to the NHS in November that donepezil, galantamine and rivastigmine should only be considered as options in the treatment of people with moderate Alzheimer's disease. Memantine is only recommended as part of clinical studies for people with moderately-severe to severe Alzheimer's disease.

Further information:

This page was last updated: 29 September 2009

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.